1 reply to this topic

[Gerald W. Gaston]

"The US Food and Drug Administration has finally approved Provenge (Sipuleucel-T) for use in treating metastisized prostate cancer as of April 29th. Provenge, which uses the body’s own immune system to hunt down and destroy cancer cells, is the first treatment of its kind to win FDA approval. The decision comes almost exactly one year after encouraging evidence from Phase III clinical trials showed that the therapy would extend life an average 4.1 months over placebo. Dendreon stock rose a hefty ~26% ($10.50) the day of the FDA approval announcement. With this burgeoning success, Dendreon and Provenge may be leading the way for other autologous immunotherapies to help revolutionize healthcare."

http://singularityhu...ge-stock-leaps/

4.1 months on average at aprox. $23,000/month and this is considered great news. Yes it is better than nothing but I was hoping it would be even more effective.

[niner]

4.1 months on average at aprox. $23,000/month and this is considered great news. Yes it is better than nothing but I was hoping it would be even more effective.

Well, look at it this way- at least the hit to your estate (or more likely, the hit to some or all of us) will only be $94,300 on average. Some revolution.